Researchers found that targeting tumor sites with radiation or surgery after initial treatment can significantly improve overall survival time for patients. Progression-free survival and toxicity data also showed benefits, with median overall survival times of up to 41.2 months.
The NRG Oncology clinical trial BR001 found that SBRT is safe for patients with 2 metastases or 3-4 metastases in specific locations, including peripheral lung and abdomen/pelvic. The study showed zero protocol-defined dose-limiting toxicities across evaluable anatomic locations.
The SPPORT trial found that adding pelvic lymph node treatment and short-term hormone therapy to standard treatment extends time before cancer spreads. This combination therapy resulted in higher freedom-from-progression rates and lower distant metastasis rates compared to standard treatments alone.
Oncologists require more education on the use of biosimilars, which could increase patient access to innovative therapies due to economic constraints. ESMO supports their use as cheaper alternatives to reference biologics, promoting sustainable and widely accessible cancer care.
A study by NRG Oncology found that short-term androgen-deprivation therapy (ADT) combined with radiotherapy improved overall survival for men with early stage prostate adenocarcinoma for up to 10.4 years. However, the benefits dissipated after 18 years.
A new study from the University of Pennsylvania found that cancer patients can safely use topical skin treatments during radiation therapy without increasing the radiation dose to their skin. The study challenged common advice given to patients and debunked the myth that these treatments increase radiation damage.
The European Society for Medical Oncology (ESMO) has launched a global initiative to integrate supportive and palliative care into cancer treatment. Twenty new institutions from Japan, Denmark, Estonia, and Qatar have been recognized as Designated Centres of Integrated Oncology and Palliative Care.
The new guideline recommends moderate hypofractionation (240-340 cGy) as an alternative to conventional fractionation for men with early-stage prostate cancer. Hypofractionated radiation therapy can be completed in four to five weeks, compared to eight to nine weeks for conventional radiation.
A team of researchers has created an automated program to screen for malnutrition in hospitalized children, using existing patient data in electronic health records. The study found a high prevalence of malnutrition among pediatric oncology patients, with 42% overall and varying levels of severity.
The ESMO 2018 Congress will feature a wide range of topics including immunotherapy, biomarkers, and prevention. The event will also host the annual congress of the European Oncology Nursing Society and a patient advocacy track emphasizing the central role of patients in securing access to optimal cancer care.
At ASTRO's Annual Meeting, leading researchers will present their groundbreaking findings on clinical trials and radiation oncology research. The meeting features three news briefings highlighting advances in breast, lung, genitourinary, oral, and oligometastatic cancers.
A Special Focus Issue on Integrative Oncology investigates complementary and integrative medicine in multiple age groups, nations, and special populations. Research articles and commentaries discuss the options and effectiveness of nutritional strategies, aromatherapy, massage, and self-care toolkits for cancer patients.
The ESMO Award 2018 is bestowed on Jean-Charles Soria, a pioneer in developing anti-cancer drugs, while Tony Mok receives the ESMO Lifetime Achievement Award for his practice-changing contribution to lung cancer. Pasi Jänne and Margaret Foti also receive awards for their translational research and mentorship efforts, respectively.
The RTOG 0618 trial found Stereotactic Body Radiation Therapy (SBRT) to achieve favorable primary tumor control and local control rates in operable early-stage lung cancer patients, with a low rate of toxicity. The results suggest that SBRT may be a viable alternative to surgery for this patient population.
A study by NRG Oncology/RTOG 0424 found that MGMT promoter methylation is associated with improved progression-free and overall survival in high-risk, low-grade glioma patients. The analysis suggests that MGMT promoter methylation should be incorporated into future clinical trial designs to risk-stratify LGG patients.
Researchers have identified a DNA-level biomarker, MGMT promoter methylation, as an independent prognostic marker of high-risk, low-grade glioma in patients treated with temozolomide and radiotherapy. This biomarker can predict patient outcomes, with patients having methylated tumors showing improved survival rates.
The ESMO 2020 Annual Congress will bring together oncology professionals from over 150 countries to learn about the latest advances in cancer treatment. The congress will feature a programme developed by international experts under the leadership of Prof John Haanen, NKI Amsterdam.
The American Society of Clinical Oncology has endorsed guidelines from the Society for Integrative Oncology, recommending integrative therapies for anxiety, depression, and quality of life improvement. However, some treatments like ginseng and acupressure require further research due to safety concerns.
The ILLUMINATE-204 trial shows an overall response rate of 38% with 2 complete responses, suggesting a promising strategy for treating patients with metastatic melanoma unresponsive to PD-1 therapy. The combination regimen is generally well-tolerated, with fewer than a quarter of patients experiencing immune-related toxicities.
Weichselbaum, Professor and Chairman of Radiation and Cellular Oncology at the University of Chicago, has made significant contributions to understanding oligometastasis. His work on curing tumors through surgery or radiation therapy has been supported by several studies demonstrating successful treatments.
Supriya G. Mohile, an oncologist at the Wilmot Cancer Institute, has been named the winner of the B.J. Kennedy Award by ASCO for her work in geriatric oncology. The award recognizes her research and efforts to improve communication between doctors and older patients with cancer.
Professor Yates received the prestigious Distinguished Researcher award from the international Oncology Nursing Society for her research on managing common problems experienced by cancer patients. The award recognizes her contributions to enhancing the science and practice of oncology nursing, particularly in Australia.
A survey of over 200 oncologists reveals that most have discussed medical marijuana use with patients, but many lack knowledge on its effectiveness. The study highlights the need for clinical trials and education to inform cancer care.
The European Organisation for the Research and Treatment of Cancer (EORTC) and ESTRO join forces to launch E2-RADIatE, a pan-European infrastructure for efficient collaboration in radiation oncology. The initiative aims to generate robust data on cancer treatment and develop new therapeutic strategies.
Researchers identified RB1 gene mutations as a mechanism underlying acquired resistance to CDK 4/6 inhibitor treatment for HR-positive breast cancer. The study found that these mutations led to loss of RB1 function and consequently resistance to CDK 4/6 inhibitors in patients whose tumors progressed after treatment.
Fabrice Barresi has been awarded the Heine H. Hansen Award by European Society for Medical Oncology (ESMO) and International Association for the Study of Lung Cancer (IASLC). This award is presented annually at the European Lung Cancer Congress to a lung cancer investigator who has made a special contribution to this field.
A recent NRG Oncology study found that high-dose radiotherapy improves biochemical control and reduces distant metastases in men with intermediate-risk prostate cancer, but does not enhance overall survival. The treatment also resulted in more side effects compared to standard radiotherapy.
A recent study found that medical students receive little formal instruction in radiation oncology, a crucial aspect of cancer treatment. The study highlights the need for radiation oncologists to take ownership over educating medical students about their specialty's value in patient care. Despite this gap, some departments reported en...
A new study published in JAMA Oncology found that higher doses of radiation therapy did not improve survival rates for patients with intermediate-risk prostate cancer. However, the study did show lower rates of recurrence and tumor growth in the group receiving the higher dose, which could lead to better quality of life.
Precision oncology uses advanced molecular diagnostic technologies to select targeted therapies, resulting in improved overall survival and lower average total healthcare costs. Average weekly costs were significantly lower for the targeted treatment group compared to the control group.
A recent study found that nearly half of all prostate cancer randomized clinical trials use lab results that disproportionately exclude black patients. The study, published in JAMA Oncology, highlights the need for researchers to adjust entry criteria to prevent racial biases.
A new algorithm provides a comprehensive guide to managing spinal metastases, integrating specialties and offering personalized treatment approaches. The algorithm focuses on spine-specific issues and incorporates popular treatment paths, including surgical decompression and stereotactic body radiotherapy.
International organizations IASLC and BTOG are partnering to spread awareness of revised lung cancer staging criteria. The new system takes effect this month and aims to provide better care for patients. Key findings highlight improved prognostic factors, tumor size measurements, and coding systems for lung cancers with multiple lesions.
Dr. Jerry A. Shields, a pioneering ophthalmologist, received the inaugural Brady-Shields Endowed Chair in Ocular Oncology at Wills Eye Hospital. The chair honors Dr. Luther W. Brady Jr., Dr. Carol L. Shields, and their contributions to ocular oncology research.
The NRG Oncology trial found that trastuzumab did not negatively affect cardiac function in patients with node-positive, HER2-positive breast cancer who survived without cancer recurrence. Both groups maintained good cardiac function at a median of 8.8 years after treatment.
The ESMO Position Paper emphasizes the need for patient-centered care in cancer treatment, addressing physical, psychological, social, and spiritual needs. It calls for increased awareness, research, education, and resources for supportive and palliative care.
The combination of chemotherapy and immunotherapy significantly improves progression-free survival in patients with advanced non-squamous NSCLC. The study showed that the addition of atezolizumab to bevacizumab and chemotherapy leads to a median PFS of 8.3 months, compared to 6.8 months with bevacizumab and chemotherapy alone.
This special focus issue of Future Oncology explores current and future image-guided interventions in oncology, including techniques such as fluorescence and optical imaging. The issue aims to provide a platform for researchers and clinicians to discuss recent advances in radiotherapy and personalized treatment approaches.
The ESMO International Consortium Study found dramatic disparities in access to anti-cancer medications, even among essential medicines recommended by the World Health Organization. In Lower Middle- and Low-Income countries, many essential medications are available only at full cost, limiting accessibility.
The Lancet Oncology Commission recommends prioritizing key areas for US$2 billion funding to advance cancer research and treatment, focusing on prevention, targeted interventions, and patient-centered data sharing. The report aims to improve cancer care for underserved groups and reduce health disparities.
Prof Laurence Zitvogel has been awarded the first ESMO Award for Immuno-Oncology for her pioneering work in advancing cancer immunology and immunotherapy. Her research focuses on understanding the gut microbiome's role in cancer immunosurveillance, with implications for predicting response to immunomodulators.
A phase III trial has confirmed the effectiveness of pelvic radiation as a standard treatment for high-risk stage I-II endometrial cancer. The study found that adjuvant pelvic radiation provided better pelvic control and fewer severe side effects compared to a brachytherapy-chemotherapy combination.
A survey of breast cancer clinic patients found that short- and long-term side effects were often better than anticipated, with 83% and 84% of respondents reporting similar expectations. Women reported lower fears and more positive experiences after treatment, highlighting the need to address misconceptions about radiation therapy.
The American Society for Radiation Oncology (ASTRO) has awarded $275,000 in research grants to four early-career scientists to investigate the effects of radiation on breast cancer cells and tumor immune evasion. The awardees aim to develop innovative treatments that improve patient outcomes by modulating the immune response.
At ESMO 2017, researchers presented 55 late-breaking abstracts and 1,736 selected abstracts, featuring breakthrough treatments for various cancers. The Congress emphasized the importance of preventing cancer through lifestyle changes and explored sustainable treatment options.
The Triggers tool identifies patients who benefit from early palliative care, improving their prognosis and quality of life. In a pilot study, the tool was successfully implemented at The Royal Marsden NHS Foundation Trust, with 75% of patients showing positive triggers for specialist palliative care.
A nationwide study in Ireland found that most oncology patients consider clinical trials important but struggle with central concepts like chance and randomization. The study aimed to understand factors influencing patients' decisions about participating in clinical trials.
The 'Triggers' tool evaluates cancer patients' palliative care needs at an earlier stage, enabling early referrals and potentially improving prognosis. A pilot study showed that 75% of patients who triggered positive on the tool items had a moderate need for specialist palliative care.
The ESMO-MCBS version 1.1 is the first major revision, introducing a new scale for single-arm studies in orphan diseases and for diseases with high unmet need. This updated tool will enable users to evaluate single-arm studies, previously only applicable to comparative studies.
ASTRO has recognized 43 researchers and clinical teams for their top-rated research abstracts, showcasing innovative science in radiation oncology. The Resident Clinical/Basic Science Research Abstract Award and Annual Meeting Travel Award also support early-career scientists, with a total of $45,000 in honorariums awarded.
Researchers have developed and validated a nomogram that can predict overall survival and progression-free survival for patients with oropharyngeal squamous cell carcinoma treated with radiation-based therapy. The nomograms were derived from clinical trials NRG Oncology/RTOG 0129 and 0522.
Many young cancer patients are not receiving adequate fertility information and support, according to a new Psycho-Oncology review of published literature. The analysis found that clinicians' lack of knowledge and unclear roles hinder the provision of fertility preservation services.
A collection of articles on hereditary cancer syndromes, including Li-Fraumeni and Lynch syndromes, has been published in JAMA Oncology. The studies focus on the effectiveness of intensive cancer surveillance programs for individuals with these rare syndromes.
The American Society for Radiation Oncology (ASTRO) has selected 23 distinguished members to receive the ASTRO Fellow designation. These individuals have made significant contributions to the field of radiation oncology in research, education, patient care, or service and leadership.
ASTRO honors Edith Peterson Mitchell, MD, a leading researcher and medical oncologist, for her work on chemoradiation treatments. Her research has helped raise the profile of radiation oncology by providing clinical evidence for combined modality treatment.
The NRG-RTOG 0436 trial found that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer. The trial showed no significant benefit from the addition of EGFR inhibitor cetuximab to standard treatment.
A new study from the University of Pennsylvania challenges common advice given to breast cancer patients, suggesting that antiperspirants can be used safely during radiotherapy. The study found no significant difference in radiation skin dose absorbed by patients with or without antiperspirants.
The European Society for Medical Oncology has announced the recipients of its four distinguished annual awards. Miguel Martin is recognized for his work in breast cancer research, while José Baselga receives the Lifetime Achievement Award for pivotal contributions to drug development. Alberto Bardelli wins the Translational Research Aw...
Søren M. Bentzen and Louis B. Harrison have made significant contributions in clinical patient care, research, teaching, and service to the profession. Dr. Bentzen focuses on personalized medicine using big data to tailor treatments, while Dr. Harrison is a renaissance man of radiation oncology with varied accomplishments.
Annals of Oncology has achieved an impressive Impact Factor score of 11.855, ranking it among the top 5% of oncology titles globally. The journal is recognized for its rapid and efficient peer-review publications on cutting-edge cancer research.